文献速递瓣膜病与结构性心脏病

DUSP26通过拮抗MDM2介导的DPP4泛素化促进主动脉瓣钙化

DUSP26 induces aortic valve calcification by antagonizing MDM2-mediated ubiquitination of DPP4 in human valvular interstitial cells.
PubMed 文献 · Eur Heart J · 2021-01-01

该研究在人类钙化主动脉瓣与正常对照中通过微阵列分析发现DUSP26显著上调。在HCD喂养的ApoE-/-小鼠中沉默DUSP26可改善主动脉瓣钙化及超声参数、降低成骨标志物,并在人瓣膜间质细胞中验证。机制上DUSP26通过拮抗MDM2介导的DPP4泛素化降解激活DPP4,促进CAVD进展。

要点

  • DUSP26在人类钙化主动脉瓣中显著上调,是CAVD的潜在治疗靶点
  • 沉默DUSP26可减轻HCD喂养ApoE-/-小鼠的主动脉瓣钙化并改善超声参数
  • DUSP26通过拮抗MDM2介导的DPP4泛素化降解激活DPP4促钙化

核心结论

  • DUSP26通过抑制DPP4降解促进主动脉瓣钙化,沉默或抑制DUSP26是延缓CAVD进展的可行治疗策略。

研究设计与样本

  • 微阵列分析比较人类钙化主动脉瓣与正常对照的基因表达。
  • ApoE-/-小鼠分别喂食正常饮食或高胆固醇饮食,感染携带DUSP26 shRNA的腺相关病毒2型以沉默DUSP26。
  • 在成骨培养基诱导的人瓣膜间质细胞中验证结果,并结合免疫沉淀、液相色谱-串联质谱和功能实验探究机制。

主要发现

  • DUSP26在人类钙化主动脉瓣中显著上调。
  • 沉默DUSP26减轻HCD喂养ApoE-/-小鼠的主动脉瓣钙化,表现为瓣叶厚度和钙沉积减少、超声参数改善(峰值跨瓣射流速度及平均跨瓣压差降低、主动脉瓣面积增加)、成骨标志物(Runx2、osterix、osteocalcin)水平降低。
  • DPP4与DUSP26相互作用介导DUSP26的促钙化效应;高N6-甲基腺嘌呤水平上调CAVD中的DUSP26,DUSP26通过拮抗MDM2介导的DPP4泛素化和降解激活DPP4,促进CAVD进展。

临床怎么用

  • DUSP26沉默或抑制可作为延缓CAVD进展的潜在治疗策略,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The morbidity and mortality rates of calcific aortic valve disease (CAVD) remain high while treatment options are limited. Here, we evaluated the role and therapeutic value of dual-specificity phosphatase 26 (DUSP26) in CAVD. METHODS AND RESULTS: Microarray profiling of human calcific aortic valves and normal controls demonstrated that DUSP26 was significantly up-regulated in calcific aortic valves. ApoE-/- mice fed a normal diet or a high cholesterol diet (HCD) were infected with adeno-associated virus serotype 2 carrying DUSP26 short-hairpin RNA to examine the effects of DUSP26 silencing on aortic valve calcification. DUSP26 silencing ameliorated aortic valve calcification in HCD-treated ApoE-/- mice, as evidenced by reduced thickness and calcium deposition in the aortic valve leaflets, improved echocardiographic parameters (decreased peak transvalvular jet velocity and mean transvalvular pressure gradient, as well as increased aortic valve area), and decreased levels of osteogenic markers (Runx2, osterix, and osteocalcin) in the aortic valves. These results were confirmed in osteogenic medium-induced human valvular interstitial cells. Immunoprecipitation, liquid chromatography-tandem mass spectrometry, and functional assays revealed that dipeptidyl peptidase-4 (DPP4) interacted with DUSP26 to mediate the procalcific effects of DUSP26. High N6-methyladenosine levels up-regulated DUSP26 in CAVD; in turn, DUSP26 activated DPP4 by antagonizing mouse double minute 2-mediated ubiquitination and degradation of DPP4, thereby promoting CAVD progression. CONCLUSION: DUSP26 promotes aortic valve calcification by inhibiting DPP4 degradation. Our findings identify a previously unrecognized mechanism of DPP4 up-regulation in CAVD, suggesting that DUSP26 silencing or inhibition is a viable therapeutic strategy to impede CAVD progression.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Wang Y, Han D, Zhou T, et al. DUSP26 induces aortic valve calcification by antagonizing MDM2-mediated ubiquitination of DPP4 in human valvular interstitial cells. Eur Heart J. 2021. PMID: 34179958. doi:10.1093/eurheartj/ehab316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。